l. brevis cd2 (VSL Pharmaceuticals)
90
Structured Review
VSL Pharmaceuticals
l. brevis cd2
L. Brevis Cd2, supplied by VSL Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l%2E+brevis+cd2/l++brevis+cd2/us11478423-540-7-11
Average 90 stars, based on 1 article reviews
L. Brevis Cd2, supplied by VSL Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l%2E+brevis+cd2/l++brevis+cd2/us11478423-540-7-11
Average 90 stars, based on 1 article reviews
l. brevis cd2 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Bacteria:Article Title: Self-film-forming composition for oral care Article Snippet: L. reuteri DSM 17938 from Biogaia (Sweden), Article Title: Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss. Article Snippet: Six-week-old C57BL/6 male mice (The Jackson Laboratory, Bar Harbor, ME, USA) were treated three times daily with L. brevis CD2 (8.2 9 105 bacteria in 1 mm2 lyopatch) or Article Title: Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss Article Snippet: Six-week-old C57BL/6 male mice (The Jackson Laboratory) were treated three times daily with L. brevis CD2 (8.2 × 10 5 bacteria in 1 mm 2 lyopatch) or Control:Article Title: Self-film-forming composition for oral care Article Snippet: L. reuteri DSM 17938 from Biogaia (Sweden), Article Title: Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss. Article Snippet: Six-week-old C57BL/6 male mice (The Jackson Laboratory, Bar Harbor, ME, USA) were treated three times daily with L. brevis CD2 (8.2 9 105 bacteria in 1 mm2 lyopatch) or Article Title: Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss Article Snippet: Six-week-old C57BL/6 male mice (The Jackson Laboratory) were treated three times daily with L. brevis CD2 (8.2 × 10 5 bacteria in 1 mm 2 lyopatch) or |